Company

Alar Pharmaceuticals, Inc.

Headquarters: Taichung, Taiwan

Employees: 19

CEO: Dr. Yung-Shun Wen Ph.D.

TWSE: 6785 +1.34%

Market Cap

TW$16.84 Billion

TWD as of July 1, 2024

US$517.3 Million

Market Cap History

Alar Pharmaceuticals, Inc. market capitalization over time

Evolution of Alar Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Alar Pharmaceuticals, Inc.

Detailed Description

Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. The company was founded in 2016 and is based in Taichung, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Alar Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: TWSE: 6785 wb_incandescent

Details

Headquarters:

No. 19, Keyuan Road

Rm. 312, 3rd Floor Xitun District

Taichung, 407

Taiwan

Phone: 886 4 2463 7115

Fax: 886 4 2256 9658